ReNeuron Group Plc Company Profile (LON:RENE)

About ReNeuron Group Plc (LON:RENE)

ReNeuron Group Plc logoReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:RENE
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: £64.08 million
  • Outstanding Shares: 3,164,618,000
Average Prices:
  • 50 Day Moving Avg: GBX 2.19
  • 200 Day Moving Avg: GBX 2.49
  • 52 Week Range: GBX 2 - GBX 3.71
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $574,000.00
  • Price / Sales: 111.64
  • Book Value: GBX 0.02 per share
  • Price / Book: 1.07
  • EBIDTA: ($17,830,000.00)
  • Average Volume: 2.64 million shs.

Frequently Asked Questions for ReNeuron Group Plc (LON:RENE)

What is ReNeuron Group Plc's stock symbol?

ReNeuron Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

Where is ReNeuron Group Plc's stock going? Where will ReNeuron Group Plc's stock price be in 2017?

2 brokers have issued 1 year price objectives for ReNeuron Group Plc's shares. Their predictions range from GBX 9 to GBX 15. On average, they anticipate ReNeuron Group Plc's share price to reach GBX 12 in the next twelve months. View Analyst Ratings for ReNeuron Group Plc.

Who are some of ReNeuron Group Plc's key competitors?

How do I buy ReNeuron Group Plc stock?

Shares of ReNeuron Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of ReNeuron Group Plc stock cost?

One share of ReNeuron Group Plc stock can currently be purchased for approximately GBX 2.03.

Analyst Ratings

Consensus Ratings for ReNeuron Group Plc (LON:RENE) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 12

Analysts' Ratings History for ReNeuron Group Plc (LON:RENE)
DateFirmActionRatingPrice TargetDetails
4/27/2017N+1 SingerReiterated RatingBuyGBX 9View Rating Details
4/4/2017Stifel NicolausReiterated RatingBuyGBX 15View Rating Details
(Data available from 5/23/2015 forward)


Earnings History for ReNeuron Group Plc (LON:RENE)
No earnings announcements for this company have been tracked by


Earnings Estimates for ReNeuron Group Plc (LON:RENE)
Current Year EPS Consensus Estimate: $-0.730 EPS


Dividend History for ReNeuron Group Plc (LON:RENE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ReNeuron Group Plc (LON:RENE)
Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Michael HuntInsiderBuy250,000GBX 3£7,500
2/17/2016Hunt,MichaelInsiderSell509,554GBX 3£15,286.62
2/12/2016Hunt,MichaelInsiderSell594,637GBX 3£17,839.11
2/11/2016Hunt,MichaelInsiderSell1,208,333GBX 3£36,249.99
2/5/2016Hunt,MichaelInsiderSell1,035,533GBX 3£31,065.99
2/2/2016Edward Berriman,JohnInsiderBuy318,476GBX 3£9,554.28
1/29/2015Olav HellebøInsiderBuy322,778GBX 3.10£10,006.12
(Data available from 1/1/2013 forward)


Headline Trends for ReNeuron Group Plc (LON:RENE)
Latest Headlines for ReNeuron Group Plc (LON:RENE)
DateHeadline logoReNeuron To Present CTX Exosome Candidate Data At London Conference - May 5 at 7:45 PM logoReNeuron Group Plc's (RENE) "Buy" Rating Reaffirmed at N+1 Singer - April 30 at 6:14 PM logoReNeuron Group Plc (RENE) Given "Buy" Rating at Stifel Nicolaus - April 8 at 6:46 PM logoGrifols SA : Overvalued relative to peers, but good fundamentals - April 7 at 12:13 PM logoHalf Year 2016 ReNeuron Group PLC Earnings Release - Before Market Open - February 10 at 10:28 PM logoDIRECTOR DEALINGS: ReNeuron CFO Buys 250,000 Shares - February 7 at 8:21 AM logoEvgen Pharma Doses First Breast Cancer Trial Patients; Hires New CFO - January 17 at 12:18 PM


Social activity is not available for this stock.


ReNeuron Group Plc (RENE) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff